ICD-10 Code for Prostate Cancer: C61, Documentation, Claims & Denials

The words “prostate cancer” point to C61 but the right diagnosis code still depends on what the provider has actually documented.

A confirmed malignancy, an elevated PSA, a screening visit, and a past history of prostate cancer are not interchangeable coding situations.

This guide explains C61, when it applies, when another code may be more appropriate, and what providers should document to support accurate prostate cancer coding. What providers should document to support accurate prostate cancer coding.

What Is the ICD-10 Code for Prostate Cancer?

The ICD-10-CM code for prostate cancer is C61 — Malignant neoplasm of prostate.

For a patient with documented active malignant neoplasm originating in the prostate, C61 identifies the primary prostate malignancy. The current FY 2026 ICD-10-CM classification lists C61 as “Malignant neoplasm of prostate.” CMS also includes C61 in its current ICD-10-CM materials for malignant neoplasms of the male reproductive system.

So, when the provider documents an established diagnosis of prostate cancer that is currently being treated, managed, or otherwise clinically relevant as an active malignancy, C61 is the primary prostate cancer diagnosis code to consider.

Is There a More Specific C61 Code?

No. The current ICD-10-CM classification does not divide C61 into additional codes based on the particular zone or lobe of the prostate.

That means coders should not create or substitute a fictional C61.x code simply because the medical record identifies a more precise anatomical location within the prostate.

The official ICD-10-CM resources from CDC/NCHS provide the current Index, Tabular List, and Table of Neoplasms used to establish the appropriate diagnosis code.

Why Does the Prostate Cancer Diagnosis Code Matter to Physicians?

The diagnosis code is not just a billing field that gets added after the clinical work is finished.

It helps connect the condition documented in the chart with the service reported on the claim.

That connection matters when a payer determines whether the service meets its coverage and medical-necessity requirements. CMS guidance states that diagnosis codes reported on a claim should best describe the patient’s condition for which the service was performed. The same guidance also notes that the medical record must support medical necessity and be available when requested.

For physicians, this creates a practical issue.

You may have performed the correct service. You may have documented the encounter. But if the diagnosis attached to the claim does not accurately represent why the service was provided, the payer may not have enough information to process it as expected.

payment is not guaranteed when the diagnosis code is right, so many other things like coverage policies, payer rules, authorization requirements, procedure coding, modifiers, and documentation can affect payment. 

What Does C61 Actually Tell the Payer?

This code “C61″ explains that the documented condition is prostate cancer rather than a benign prostate condition, an abnormal laboratory finding, or simply a history of cancer. That distinction can matter for services connected to diagnosis, treatment, surveillance, imaging, procedures, or other cancer-related care.

For example, CMS currently lists C61 as a diagnosis supporting medical necessity for certain transrectal ultrasound services. It also lists other prostate-related diagnoses, including R97.20, R97.21, and Z85.46, depending on the service and circumstances.

The question is not only, “What is the patient’s diagnosis?”

It is also:

“Does the diagnosis reported on this claim accurately explain the service being performed today?”

Does Prostate Cancer Stage Change the C61 Code?

Not necessarily. One common misunderstanding is that physicians or their billing teams should look for a different C61 code based on the cancer’s stage, Gleason score, or risk group.

C61 itself identifies the primary malignant neoplasm of the prostate. The clinical record can contain considerably more information than the ICD-10-CM code communicates.

For example, the chart might document:

• Gleason score
• Grade Group
• PSA level
• tumor characteristics
• localized disease
• regional involvement
• metastatic disease
• treatment history
• current treatment plan

Those details remain clinically important. They help explain the patient’s condition and treatment, but they do not mean that C61 suddenly becomes a different prostate cancer code.

If the patient has documented secondary malignancy, the additional site may need to be coded separately according to the applicable coding guidelines.

What if the cancer has spread?

This is where simply reporting “prostate cancer” may not tell the entire story.

If prostate cancer has metastasized to bone and the secondary malignancy is documented, C79.51 — Secondary malignant neoplasm of bone may also be relevant. CMS’s current coding resources include C79.51 among prostate-related diagnosis codes used to support certain services.

The important point for physicians is documentation.

Don’t expect the billing process to fill in clinical details that were never documented. If metastatic disease is known and clinically relevant to the encounter, the medical record should make that clear.

C61 vs. Z85.46: Active Cancer or History?

This is one of the areas where an old diagnosis can create confusion. Just know these codes are not interchangeable. 

• C61 describes malignant neoplasm of the prostate.
• Z85.46 describes a personal history of malignant neoplasm of the prostate.

Let’s take an example of a patient that was diagnosed with prostate cancer several years ago, has completed the treatment, and is now being seen  for routine follow-up with no current evidence of active malignancy. The clinical situation is different from that of a patient receiving active treatment for prostate cancer.

That does not mean a physician should independently decide which diagnosis produces the best reimbursement. The diagnosis reported should reflect the patient’s documented condition and the applicable coding rules.

The key takeaway is simpler:

Do not let an old prostate cancer diagnosis automatically become the diagnosis for every future encounter.

Review the current clinical picture. If the patient’s status has changed, the documentation and coding may need to change with it.

What About Rising PSA After Prostate Cancer Treatment?

R97.21 is the ICD-10-CM code for rising PSA following treatment for malignant neoplasm of prostate. CMS includes this code in its prostate-related billing and coding guidance.

That is different from simply saying that a patient has prostate cancer. For example, a patient with previously treated prostate cancer and rising PSA levels should have the current reason for the visit clearly documented.

This is where clinical documentation can make the billing process much easier. The note should tell the story of the encounter.

What was the physician evaluating? What changed? What does the PSA trend mean clinically? Is recurrent or persistent malignancy suspected or established? What is the plan? The code selection should follow the documented clinical situation and applicable coding guidance.

Documentation Gaps That Can Put Prostate Cancer Claims at Risk

A physician may know exactly what is happening with a patient and still have a documentation problem. That usually happens when important information stays in the physician’s head rather than making it into the medical record.

The cancer status is unclear

A note that simply says “prostate cancer” may not give enough context for every encounter. If the patient’s treatment status or current disease status matters to the service, document it clearly.

The assessment does not explain the service

The procedure may be obvious to the physician, but the payer reviews the information that appears on the claim and in the supporting record. If the diagnosis and service seem unrelated, additional review can follow.

Old diagnoses remain unchanged

Problem lists are useful, but they should not replace an assessment of the patient’s current condition. If the patient’s cancer status has changed, the documentation should reflect that change.

Metastatic disease is not clearly documented

If a secondary malignancy is known, specify the site when clinically appropriate. Vague language can make the claim harder to interpret.

PSA-related encounters lack context

An elevated or rising PSA should not be treated as interchangeable with confirmed prostate cancer.

How Incorrect Diagnosis Coding Can Affect Practice Revenue

It is tempting to think of an ICD-10 error as a small administrative issue.

It isn’t always. A diagnosis mismatch can contribute to:

Claim rejection → manual correction → resubmission → delayed payment

 Or:

Claim submission → payer review → records request → additional staff work → delayed reimbursement

And in some cases:

Claim denial → appeal → more administrative time → payment delayed further

CMS notes that claims lacking necessary information may be returned as incomplete, and its billing guidance emphasizes that diagnosis codes should accurately describe the condition for which the service was performed.

That is why diagnosis accuracy has a revenue-cycle consequence even though the physician does not personally submit every claim. Every avoidable correction takes someone’s time. If the same issue appears across dozens of claims, the cost becomes much more noticeable.

Common Prostate Cancer Coding Mistakes to Watch For

A few recurring problems deserve extra attention.

The goal isn’t to add more words to every clinical note. It is to make the important information visible.

What Should Physicians Check Before a Prostate Cancer Claim Is Submitted?

A quick review can catch issues before the payer does.

Ask whether the diagnosis reflects what is being evaluated or treated today, rather than what happened years ago.

The medical record should contain enough information to support the diagnosis being reported.

A payer should be able to understand the clinical connection between the documented condition and the service.

Treatment, remission, recurrence, surveillance, and active disease can represent different clinical circumstances.

If secondary malignancy is known and relevant, make sure the record clearly identifies it.

When PSA is the reason for follow-up, document the clinical context rather than leaving the reader to interpret a laboratory value.

Even a correctly coded C61 claim can face problems if an authorization, coverage requirement, procedure code, modifier, or other payer rule has not been met.

A Quick Reference for Prostate Cancer ICD-10 Coding

Here is the short version physicians and practice teams can keep handy:

This table is a starting point, not a substitute for reviewing the full documentation and applicable coding guidelines. The correct diagnosis depends on the patient’s actual clinical circumstances.

Why Getting C61 Right Is More Than a Coding Exercise

Many practices encounter prostate cancer, particularly urology, oncology, radiation oncology, and primary care. An estimated 333,830 new cases in the U.S. in 2026, accurate documentation and coding matter.

The goal is not to choose a code based on reimbursement. It is to make sure the documentation, diagnosis code, and billed service accurately reflect the care provided. Clear records can also help prevent unnecessary claim questions and delays..

C61 may be only three characters, but the documentation behind those three characters matters.

Frequently Asked Questions

What is the ICD-10 code for prostate cancer?

The ICD-10-CM code for malignant neoplasm of the prostate is C61. The code should be reported when supported by the patient’s documented clinical condition and the applicable coding guidelines.

Is C61 a billable ICD-10 code?

C61 is an ICD-10-CM code for malignant neoplasm of the prostate and is used in current CMS coding resources.

What is the ICD-10 code for a history of prostate cancer?

Z85.46 is the ICD-10-CM code for personal history of malignant neoplasm of prostate. It represents a history of prostate cancer rather than automatically indicating active malignancy.

What is the ICD-10 code for rising PSA after prostate cancer treatment?

R97.21 describes rising PSA following treatment for malignant neoplasm of prostate. The physician’s documentation should explain the reason for the follow-up and the clinical context.

Does Gleason score create a different prostate cancer ICD-10 code?

C61 identifies malignant neoplasm of the prostate. Clinical information such as Gleason score and Grade Group remains important for patient care and documentation but does not turn C61 into a different prostate-site code.

Can a prostate cancer claim still be denied when C61 is correct?

Yes. An accurate diagnosis code does not guarantee payment. Coverage rules, medical necessity, authorization, procedure coding, documentation, and payer-specific requirements can all affect claim processing. CMS specifically notes that the correct use of an ICD-10-CM code does not by itself assure coverage of a service.

What is the biggest documentation issue physicians should watch for?

One of the most important is making the patient’s current disease status clear. A diagnosis carried forward from an earlier encounter may not accurately describe what is happening today. Reviewing the assessment before the claim is submitted can help prevent that mismatch.

Final Takeaway

For most confirmed prostate cancer cases, C61 is the key ICD-10-CM diagnosis code. But accurate prostate cancer coding does not end when C61 is selected.

The diagnosis needs to match the patient’s current condition, the medical record needs to support that diagnosis, and the claim should make sense alongside the service being billed. Paying attention to those connections can help physicians and their practice teams reduce avoidable claim corrections, documentation requests, and denials while keeping the clinical record accurate.